# Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).

> **NCT04663750** · PHASE3 · RECRUITING · sponsor: **King's College Hospital NHS Trust** · enrollment: 210 (estimated)

## Conditions studied

- Eye Diseases
- Macular Degeneration, Wet
- Sub-Macular Hemorrhage

## Interventions

- **PROCEDURE:** Pars plana vitrectomy
- **DRUG:** Intravitreal 2 mg aflibercept will be injected at baseline then monthly for two further doses, then 2-monthly until month 12
- **DRUG:** subretinal injection of recombinant TPA (Alteplase) up to a maximum of 25 micrograms in 0.2 mls
- **DRUG:** Intravitreal 20% sulfahexafluoride (SF6) gas tamponade

## Key facts

- **NCT ID:** NCT04663750
- **Lead sponsor:** King's College Hospital NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-04-16
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 210 (ESTIMATED)
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04663750

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04663750, "Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).". Retrieved via AI Analytics 2026-08-08 from https://api.ai-analytics.org/clinical/NCT04663750. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*